염증성 장질환 치료제 시장 : 시장 규모, 점유율, 성장률, 산업 분석, 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of inflammatory bowel disease (IBD) treatment Market

The global inflammatory bowel disease (IBD) treatment market is steadily expanding due to the rising prevalence of chronic gastrointestinal disorders such as Crohn's disease and ulcerative colitis. The market was valued at USD 29.57 billion in 2025 and is projected to grow to USD 31.24 billion in 2026, reaching USD 41.64 billion by 2034, exhibiting a CAGR of 3.66% during the forecast period. North America dominated the market with a 41.01% share in 2025, driven by strong healthcare infrastructure and high adoption of advanced biologics.

Inflammatory bowel disease affects over 0.3% of the global population, making it a significant healthcare concern. Factors such as lifestyle changes, environmental influences, genetic predisposition, and immune system dysfunction are contributing to the increasing incidence of these diseases. Growing awareness, early diagnosis, and favorable reimbursement policies in developed economies are boosting the demand for effective treatment solutions.

Market Trends

Increasing Focus on Advanced Research and Personalized Medicine

Technological advancements, including single-cell RNA sequencing and mass cytometry, are transforming IBD treatment. These technologies enable a deeper understanding of disease mechanisms, helping develop targeted therapies and personalized treatment approaches. Increasing collaborations between research institutions and pharmaceutical companies are accelerating innovation in the field.

Market Growth Drivers

Rising Prevalence of IBD

The increasing number of patients diagnosed with Crohn's disease and ulcerative colitis is a key driver of market growth. Genetic factors, lifestyle changes, and environmental triggers are contributing to the growing disease burden. Higher awareness and improved diagnostic capabilities are also increasing the number of patients undergoing treatment.

Strong Pipeline of Therapeutics

Pharmaceutical companies are actively investing in research and development to expand their product pipelines. With over 145 active clinical trials, many drugs are in advanced stages of development. The growing availability of biologics, TNF inhibitors, IL inhibitors, and JAK inhibitors is significantly improving treatment outcomes and driving market expansion.

Market Restraints

High Cost of Treatment

One of the major challenges in the market is the high cost of IBD therapies, particularly biologics. Treatment costs can range significantly per patient annually, limiting accessibility in developing regions. Additionally, limited reimbursement policies in emerging economies such as India and China further restrict market growth.

Market Segmentation Analysis

By Disease Indication

The market is segmented into Crohn's disease and ulcerative colitis. The Crohn's disease segment is expected to dominate with a 63.78% share in 2026, driven by increasing prevalence and treatment rates globally. The ulcerative colitis segment is also growing due to rising drug approvals and improved treatment accessibility.

By Route of Administration

Based on route of administration, the market is divided into oral and injectable drugs. The injectables segment dominated with a 77.58% share in 2026, primarily due to the widespread use of biologics administered via injections. Oral medications are gaining traction due to convenience and ease of use.

By Drug Class

The market includes TNF inhibitors, IL inhibitors, JAK inhibitors, anti-integrin, corticosteroids, and others. TNF inhibitors led the market with a 58.77% share in 2026, owing to their high efficacy in inducing and maintaining remission. JAK inhibitors are also gaining popularity due to their rapid onset of action.

By Distribution Channel

The market is segmented into hospital pharmacies and retail pharmacies. The hospital pharmacy segment dominated with a 95.36% share in 2026, supported by reimbursement policies and the need for specialized drug administration.

Regional Insights

North America

North America led the market with USD 12.13 billion in 2025 and is projected to reach USD 12.81 billion in 2026. Growth is driven by advanced biologic therapies, favorable reimbursement systems, and increasing disease prevalence.

Europe

Europe accounted for USD 9.69 billion in 2025, expected to reach USD 10.28 billion in 2026. The region benefits from strong regulatory support and availability of innovative therapies.

Asia Pacific

Asia Pacific held USD 5.81 billion in 2025 and is projected to reach USD 6.12 billion in 2026. Increasing awareness, improving healthcare infrastructure, and rising drug approvals are driving growth in the region.

Latin America and Middle East & Africa

Latin America reached USD 1.19 billion in 2025, while the Middle East & Africa accounted for USD 0.76 billion. Both regions are experiencing gradual growth due to rising healthcare investments and awareness.

Competitive Landscape

The market is consolidated, with major players including AbbVie Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Johnson & Johnson, Bristol-Myers Squibb, and Celltrion. These companies are focusing on product innovation, regulatory approvals, and strategic collaborations to strengthen their market position.

Conclusion

The global inflammatory bowel disease treatment market is set for steady growth, driven by rising disease prevalence, advancements in biologics, and increasing research activities. Although high treatment costs and limited reimbursement in emerging economies pose challenges, continuous innovation and expanding therapeutic options are expected to enhance patient outcomes. With the market projected to reach USD 41.64 billion by 2034, the IBD treatment industry will play a crucial role in addressing the growing global burden of chronic gastrointestinal diseases.

Segmentation By Disease Indication

• Ulcerative Colitis
• Crohn's Disease

By Route of Administration

• Oral
• Injectables

By Drug Class

• IL Inhibitors
• TNF Inhibitors
• Anti-integrin
• JAK Inhibitors
• Corticosteroids
• ASA Drugs
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy & Other

By Geography

• North America (By Disease Indication, By Route of Administration, By Drug Class, By Distribution Channel, and By Country)
  • U.S. (By Disease Indication)
  • Canada (By Disease Indication)
• Europe (By Disease Indication, By Route of Administration, By Drug Class, By Distribution Channel, and By Country)
  • U.K. (By Disease Indication)
  • Germany (By Disease Indication)
  • France (By Disease Indication)
  • Italy (By Disease Indication)
  • Spain (By Disease Indication)
  • Scandinavia (By Disease Indication)
  • Rest of Europe (By Disease Indication)
• Asia Pacific (By Disease Indication, By Route of Administration, By Drug Class, By Distribution Channel, and By Country)
  • China (By Disease Indication)
  • Japan (By Disease Indication)
  • India (By Disease Indication)
  • Australia (By Disease Indication)
  • Southeast Asia (By Disease Indication)
  • Rest of Asia Pacific (By Disease Indication)
• Latin America (By Disease Indication, By Route of Administration, By Drug Class, By Distribution Channel, and By Country)
  • Brazil (By Disease Indication)
  • Mexico (By Disease Indication)
  • Rest of Latin America (By Disease Indication)
• Middle East & Africa (By Disease Indication, By Route of Administration, By Drug Class, By Distribution Channel, and By Country)
  • GCC (By Disease Indication)
  • South Africa (By Disease Indication)
  • Rest of MEA (By Disease Indication)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Crohn's Disease, By Key Regions/Countries, 2025
• 4.2. Prevalence of Ulcerative Colitis, By Key Regions/Countries, 2025
• 4.3. Average Length of Therapy for Inflammatory Bowel Disease
• 4.4. Statistical Overview of Patients Undergoing Different Therapies
• 4.5. Pricing and Margin Analysis
• 4.6. New Product Launches, By Key Players
• 4.7. Key Industry Developments - Mergers, Acquisitions, and Partnerships
• 4.8. Pipeline Analysis, By Key Players
• 4.9. COVID-19 Impact on the Market

5. Global Inflammatory Bowel Disease Treatment Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Disease Indication
  • 5.1.1. Ulcerative Colitis
  • 5.1.2. Crohn's Disease
• 5.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.2.1. Oral
  • 5.2.2. Injectables
• 5.3. Market Analysis, Insights and Forecast - By Drug Class
  • 5.3.1. IL Inhibitors
  • 5.3.2. TNF Inhibitors
  • 5.3.3. Anti-integrin
  • 5.3.4. JAK Inhibitors
  • 5.3.5. Corticosteroids
  • 5.3.6. ASA Drugs
  • 5.3.7. Others
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital Pharmacy
  • 5.4.2. Retail Pharmacy & Others
• 5.5. Market Analysis, Insights and Forecast - By Geography
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Inflammatory Bowel Disease Treatment Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Disease Indication
  • 6.1.1. Ulcerative Colitis
  • 6.1.2. Crohn's Disease
• 6.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.2.1. Oral
  • 6.2.2. Injectables
• 6.3. Market Analysis, Insights and Forecast - By Drug Class
  • 6.3.1. IL Inhibitors
  • 6.3.2. TNF Inhibitors
  • 6.3.3. Anti-integrin
  • 6.3.4. JAK Inhibitors
  • 6.3.5. Corticosteroids
  • 6.3.6. ASA Drugs
  • 6.3.7. Others
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Hospital Pharmacy
  • 6.4.2. Retail Pharmacy & Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
    • 6.5.1.1. By Disease Indication
  • 6.5.2. Canada
    • 6.5.2.1. By Disease Indication

7. Europe Inflammatory Bowel Disease Treatment Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Disease Indication
  • 7.1.1. Ulcerative Colitis
  • 7.1.2. Crohn's Disease
• 7.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.2.1. Oral
  • 7.2.2. Injectables
• 7.3. Market Analysis, Insights and Forecast - By Drug Class
  • 7.3.1. IL Inhibitors
  • 7.3.2. TNF Inhibitors
  • 7.3.3. Anti-integrin
  • 7.3.4. JAK Inhibitors
  • 7.3.5. Corticosteroids
  • 7.3.6. ASA Drugs
  • 7.3.7. Others
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Hospital Pharmacy
  • 7.4.2. Retail Pharmacy & Others
• 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.5.1. U.K.
    • 7.5.1.1. By Disease Indication
  • 7.5.2. Germany
    • 7.5.2.1. By Disease Indication
  • 7.5.3. France
    • 7.5.3.1. By Disease Indication
  • 7.5.4. Spain
    • 7.5.4.1. By Disease Indication
  • 7.5.5. Italy
    • 7.5.5.1. By Disease Indication
  • 7.5.6. Scandinavia
    • 7.5.6.1. By Disease Indication
  • 7.5.7. Rest of Europe
    • 7.5.7.1. By Disease Indication

8. Asia Pacific Inflammatory Bowel Disease Treatment Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Disease Indication
  • 8.1.1. Ulcerative Colitis
  • 8.1.2. Crohn's Disease
• 8.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.2.1. Oral
  • 8.2.2. Injectables
• 8.3. Market Analysis, Insights and Forecast - By Drug Class
  • 8.3.1. IL Inhibitors
  • 8.3.2. TNF Inhibitors
  • 8.3.3. Anti-integrin
  • 8.3.4. JAK Inhibitors
  • 8.3.5. Corticosteroids
  • 8.3.6. ASA Drugs
  • 8.3.7. Others
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Hospital Pharmacy
  • 8.4.2. Retail Pharmacy & Others
• 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.5.1. Japan
    • 8.5.1.1. By Disease Indication
  • 8.5.2. China
    • 8.5.2.1. By Disease Indication
  • 8.5.3. India
    • 8.5.3.1. By Disease Indication
  • 8.5.4. Australia
    • 8.5.4.1. By Disease Indication
  • 8.5.5. Southeast Asia
    • 8.5.5.1. By Disease Indication
  • 8.5.6. Rest of Asia Pacific
    • 8.5.6.1. By Disease Indication

9. Latin America Inflammatory Bowel Disease Treatment Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Disease Indication
  • 9.1.1. Ulcerative Colitis
  • 9.1.2. Crohn's Disease
• 9.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.2.1. Oral
  • 9.2.2. Injectables
• 9.3. Market Analysis, Insights and Forecast - By Drug Class
  • 9.3.1. IL Inhibitors
  • 9.3.2. TNF Inhibitors
  • 9.3.3. Anti-integrin
  • 9.3.4. JAK Inhibitors
  • 9.3.5. Corticosteroids
  • 9.3.6. ASA Drugs
  • 9.3.7. Others
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Hospital Pharmacy
  • 9.4.2. Retail Pharmacy & Others
• 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.5.1. Brazil
    • 9.5.1.1. By Disease Indication
  • 9.5.2. Mexico
    • 9.5.2.1. By Disease Indication
  • 9.5.3. Rest of Latin America
    • 9.5.3.1. By Disease Indication

10. Middle East & Africa Inflammatory Bowel Disease Treatment Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Disease Indication
  • 10.1.1. Ulcerative Colitis
  • 10.1.2. Crohn's Disease
• 10.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.2.1. Oral
  • 10.2.2. Injectables
• 10.3. Market Analysis, Insights and Forecast - By Drug Class
  • 10.3.1. IL Inhibitors
  • 10.3.2. TNF Inhibitors
  • 10.3.3. Anti-integrin
  • 10.3.4. JAK Inhibitors
  • 10.3.5. Corticosteroids
  • 10.3.6. ASA Drugs
  • 10.3.7. Others
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Hospital Pharmacy
  • 10.4.2. Retail Pharmacy & Others
• 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.5.1. GCC Countries
    • 10.5.1.1. By Disease Indication
  • 10.5.2. South Africa
    • 10.5.2.1. By Disease Indication
  • 10.5.3. Rest of Middle East & Africa
    • 10.5.3.1. By Disease Indication

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Pfizer Inc.
    • 11.2.1.1. Overview
    • 11.2.1.2. Product
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. CELLTRION INC.
    • 11.2.2.1. Overview
    • 11.2.2.2. Product
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Johnson & Johnson Services, Inc.
    • 11.2.3.1. Overview
    • 11.2.3.2. Product
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. AbbVie Inc.
    • 11.2.4.1. Overview
    • 11.2.4.2. Product
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Takeda Pharmaceutical Company Limited
    • 11.2.5.1. Overview
    • 11.2.5.2. Product
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. UCB S.A.
    • 11.2.6.1. Overview
    • 11.2.6.2. Product
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Bausch Health Companies Inc.
    • 11.2.7.1. Overview
    • 11.2.7.2. Product
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Bristol-Myers Squibb Company
    • 11.2.8.1. Overview
    • 11.2.8.2. Product
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Eli Lilly and Company
    • 11.2.9.1. Overview
    • 11.2.9.2. Product
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. Gilead Sciences
    • 11.2.10.1. Overview
    • 11.2.10.2. Product
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)
  • 11.2.11. EA Pharma Co., Ltd
    • 11.2.11.1. Overview
    • 11.2.11.2. Product
    • 11.2.11.3. SWOT Analysis
    • 11.2.11.4. Recent Developments
    • 11.2.11.5. Strategies
    • 11.2.11.6. Financials (Based on Availability)